Amanta Healthcare Ltd Q1 FY27 Earnings Analysis

- SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28. - New product pipeline of 20 products in inhalation and ophthalmic segments to commercialize in FY27-28, supporting growth. - Export revenue grew from 32% in FY25 to 39% in FY26; active marketing in 25-30 countries with key markets including UK, Thailand, Philippines, South Sudan. - Export markets like East Africa show cyclical buying patterns; export sales generally stronger in H2. - Domestic IV fluid demand growing at 8-10% year-on-year, with two-port systems growing faster at 12-13%. - Capacity ramp-up expected to reach full utilization within 3-4 months post commissioning, driving scale and margin expansion. - Solar power project to reduce costs and boost profitability from FY27 onwards. - Overall, growth driven by capacity expansion, new specialized products, and export market expansion.

- FY26 PAT margin stood at 5%, with PAT growing 42% YoY, supported by better operating leverage and reduced finance cost. - SteriPort expansion expected to increase EBITDA margin from 22% to around 24-25% with a 27% EBITDA margin from the new SteriPort line. - SteriPort line commissioning by June-end, expected contribution of INR 80-85 crores revenue in FY27 (three quarters), with full impact INR 110-120 crores in FY28. - PAT margin of 5-6% sustainable short-term; expected to improve by at least 3% post-leveraging. - Growth driven by expanding higher-value product lines like SteriPort, inhalation solutions, and ophthalmic products with 20 products in pipeline. - Lower finance cost due to debt refinancing and repayment expected to disproportionately boost PAT growth versus EBITDA. - Overall, steady revenue growth, margin expansion, and improved profitability projected through product portfolio and capacity expansions.

- SteriPort expansion: Commissioning expected by June 2026, aiming for operational by June 20; will add approx. INR110-120 crore top line from FY27 onwards with EBITDA margin around 27%. - SVP (Small Volume Parenteral) line: To be commissioned in late 2026 (October-December), focusing on inhalation and ophthalmic product pipelines, expected commercialization in FY27-28. - Solar power project: 10.8 MW captive solar plant to be commissioned by May 2026, expected to reduce power costs by about INR75 lakh per month starting FY27, improving cost efficiency and ESG profile. - Product pipeline: Currently developing 20 products primarily in inhalation and ophthalmic segments to enhance higher-margin and specialized products. - Focus on regulatory approvals and portfolio expansion to enter regulated markets alongside semi-regulated and emerging markets. These strategic investments aim to drive revenue growth, margin expansion, and operational efficiencies in upcoming years.

- The company has recently completed a refinancing exercise post-IPO, replacing higher-cost debt with lower-cost borrowings, resulting in a significant reduction in finance cost. - Currently, about 90% of the company's borrowings are at single-digit interest rates. - The total debt as of March 26 was INR 234 crore, which has reduced to INR 204 crore in early April after repayment. - Management expects to further replace around INR 30 crore to INR 40 crore of existing debt with cheaper debt within the next six months. - There is no mention of any ongoing or planned equity fundraising. - The company remains focused on maintaining a disciplined balance sheet while investing for long-term growth. Hence, while the company is actively managing and reducing its debt cost, no specific new debt or equity fundraising is announced or planned immediately.

- Amanta Healthcare Limited does not maintain a long-term order book extending over one year. - Export orders are rolling and cyclic, with visibility of around 3 to 6 months in some markets. - For example, the East African market's significant purchases happen from September to March, and export numbers tend to be better in H2 than H1. - Markets like Southeast Asia show consistent order patterns throughout the year. - The management currently does not have exact quantified numbers for the next quarter's order book but may share it separately. - The company operates primarily on distributor-based orders rather than fixed long-term contracts.